Monoclonal antibody against N2 neuraminidase of cold adapted A/Leningrad/134/17/57 (H2N2) enables efficient generation of live attenuated influenza vaccines

Shcherbik, Svetlana; Carney, Paul; Pearce, Nicholas; Stevens, James; Dugan, Vivien G.; Wentworth, David E.; Bousse, Tatiana

doi:10.1016/j.virol.2018.07.005

i

Monoclonal antibody against N2 neuraminidase of cold adapted A/Leningrad/134/17/57 (H2N2) enables efficient generation of live attenuated influenza vaccines

Supporting Files

July 12 2018
By Shcherbik, Svetlana ; Carney, Paul ; Pearce, Nicholas ; ...

File Language:

English

Details

Journal Article:

Virology
Personal Author:

Shcherbik, Svetlana ; Carney, Paul ; Pearce, Nicholas ; Stevens, James ; Dugan, Vivien G. ; Wentworth, David E. ; Bousse, Tatiana
Description:

Cold adapted influenza virus A/Leningrad/134/17/57 (H2N2) is a reliable master donor virus (Len/17-MDV) for preparing live attenuated influenza vaccines (LAIV). LAIVs are 6:2 reasortants that contain 6 segments of Len/17-MDV and the hemagglutinin (HA) and neuraminidase (NA) of contemporary circulating influenza A viruses. The problem with the classical reassortment procedure used to generate LAIVs is that there is limited selection pressure against NA of the Len/17-MDV resulting in 7:1 reassortants with desired HA only, which are not suitable LAIVs. The monoclonal antibodies (mAb) directed against the N2 of Len/17-MDV were generated. 10C4-8E7 mAb inhibits cell-to-cell spread of viruses containing the Len/17-MDV N2, but not viruses with the related N2 from contemporary H3N2 viruses. 10C4-8E7 antibody specifically inhibited the Len/17-MDV replication in vitro and in ovo but didn't inhibit replication of H3N2 or H1N1pdm09 reassortants. Our data demonstrate that addition of 10C4-8E7 in the classical reassortment improves efficiency of LAIV production.
Subjects:

Animals Antibodies, Monoclonal Antibodies, Viral Article Cell Line Classical Reassortment Cold Temperature Humans Influenza Influenza A Virus, H2N2 Subtype Influenza Vaccines Live Vaccine Monoclonal Antibody Neuraminidase Reassortant Viruses Technology, Pharmaceutical Vaccines, Attenuated Viral Proteins Virus Cultivation
Source:

Virology. 522:65-72
DOI:

http://dx.doi.org/10.1016/j.virol.2018.07.005
Pubmed ID:

30014859
Pubmed Central ID:

PMC6498426
Document Type:

Text ; Journal Article
Funding:

CC999999/Intramural CDC HHS/United States
Genre:

Journal Article
Volume:

522
Collection(s):

CDC Public Access
Main Document Checksum:

urn:sha-512:1623b4a86d0f7a42c01728c4a9e9f4ccfd0774c4decf1f36f5ddcbefac4060a37ba5ca1a33e87ed6fbe427555a73f0db5e483278ed327e4879993b57cb9859d4
Download URL:

https://stacks.cdc.gov/view/cdc/78336/cdc_78336_DS1.pdf
File Type:

[PDF - 964.72 KB ]

File Language:

English

ON THIS PAGE

Details Supporting Files

CDC STACKS serves as an archival repository of CDC-published products including scientific findings, journal articles, guidelines, recommendations, or other public health information authored or co-authored by CDC or funded partners.

As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.